The Hashtag
#InsulinPricingCrisis became a rallying cry for Type 1 diabetics and advocates highlighting the tripling of insulin prices between 2002-2013, from $40 to $130+ per vial, forcing rationing, GoFundMe campaigns, and deaths. The movement exposed pharmaceutical monopoly pricing, patent evergreening strategies, and the deadly consequences of treating life-sustaining medication as profit centers.
Timeline
2016-2017: Viral stories of diabetics rationing insulin, dying from under-dosing (Alec Smith, 26, died June 2017 after rationing due to losing insurance). Eli Lilly, Novo Nordisk, and Sanofi controlled 99% of U.S. insulin market.
2018-2019: Minnesota attorney general sued insulin manufacturers for price-fixing. #Insulin4All protests at pharmaceutical headquarters. Bernie Sanders led bus trips to Canada for affordable insulin ($30 vs $300 in U.S.).
2020-2021: Trump executive order on insulin pricing, reversed then reinstated variably. Some states passed insulin price caps ($35/month in Colorado, Illinois, others).
2022-2023: Inflation Reduction Act capped insulin at $35/month for Medicare recipients only (40% of diabetics still uncovered). Eli Lilly announced $35 cap voluntarily under pressure.
Cultural Impact
- Pharmaceutical Greed Symbol: Insulin became the poster child for U.S. healthcare dysfunction—inexpensive to produce ($2-4/vial), sold for $250-300, unchanged since 1920s discovery
- Rationing Deaths: Estimated 1 in 4 diabetics rationed insulin; documented deaths (Alec Smith, Josh Wilkerson, Antavia Worsham) personalized crisis
- GoFundMe Healthcare: Diabetics crowdfunding monthly medication illustrated systemic failure, normalizing medical bankruptcy prevention through charity
- Patent Evergreening Exposed: Drug companies making minor formula tweaks to extend monopolies for century-old medication, blocking generic competition
- Bipartisan Rare Agreement: Both left (Medicare for All advocates) and right (free market advocates) criticized pricing, though solutions differed
- Cross-Border Medication: Americans traveling to Canada, Mexico for 1/10th price exposed international pricing disparities, questioning U.S. exceptionalism claims
- Advocacy Success (Limited): State caps and eventual $35 Medicare cap showed grassroots pressure working, but still left millions uncapped
The crisis illustrated how life-sustaining medications became profit centers, the human cost of pharmaceutical monopolies, and the limitations of employer-based insurance systems leaving gaps between jobs or at age 26.
Sources: T1International advocacy reports, JAMA insulin pricing studies, Minnesota AG lawsuit documents, American Diabetes Association policy briefs, news coverage 2016-2023.